Epidemiology, clinical data, and treatment of viral hepatitis in a large cohort of intravenous drug users

Journal of Addiction Medicine

Volumn 7, Issue 1, 2013, Pages 52-57

  Gigi, Eleni ^a   Sinakos, Emmanouil ^a   Sykja, Albana ^a   Androulakis, Georgios ^b   Tanis, Christos ^b   Stayridou, Victoria ^b   Tsirogianni, Effrosyni ^b   Zouridakis, Konstantinos ^a   Bellou, Aristea Lia ^a   Orfanou, Eleni ^a   Raptopoulou Gigi, Maria ^a  

^a ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^b Organization Against Drugs   (Greece)

Author keywords

Hepatitis B and C prevalence; Hepatitis C transmission; Hepatitis C treatment; Intravenous drug users; Substitution and drugfree programs

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; BUPRENORPHINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; INTERFERON; METHADONE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS DNA; VIRUS RNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; FEMALE; FOLLOW UP; GENOTYPE; GREECE; HEPATITIS B; HEPATITIS C; HEROIN DEPENDENCE; HUMAN; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD; VIRUS TRANSMISSION;

ADULT; ANTIVIRAL AGENTS; COINFECTION; DISEASE MANAGEMENT; DRUG USERS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; MALE; MEDICATION ADHERENCE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); POLYETHYLENE GLYCOLS; PREVALENCE; RIBAVIRIN; SEROEPIDEMIOLOGIC STUDIES; SUBSTANCE ABUSE, INTRAVENOUS; TREATMENT OUTCOME; UNITED STATES; VACCINATION;

EID: 84877995768     PISSN: 19320620     EISSN: 19353227     Source Type: Journal    
DOI: 10.1097/ADM.0b013e318279756f     Document Type: Article

References (22)

1. Alter MJ. Prevention of spread of hepatitis C. Hepatology 2002;36(5)(suppl 1):S593-S598.
2. Cournot M, Gilbert A, Castel F, et al. Management of hepatitis C in active drug users: experience of an addiction care hepatology unit. Clin Biol 2004;28: 533-539.
3. Edlin BR, Carden MR. Injection drug users: the overlooked core of hepatitis C epidemic. Clin Infect Dis 2006;42: 673-676.
4. Edlin BR. Prevention and treatment of hepatitis C in injection drug users. Hepatology 2002;35(5)(suppl 1):S210-S219.
5. European Monitoring Centre for Drugs and Drug Addiction. 2010 National report (2009 data) to the EMCDDAby Reitox National Focal Point. Athens, Greece: European Monitoring Centre for Drugs and Drug Addiction.
6. Gigi E, Sinakos E, Lalla TH, Vrettou E, Orphanou E, Raptopoulou M. Treatment of intravenous drug userswith chronic hepatitis C: treatment response, compliance and side effects. Hippokratia 2007;11: 196-198.
7. Grebely J, Dore GJ. Prevention of hepatitis C virus in injecting drug users: a narrow window of opportunity. J Infect Dis 2011;203: 571-574.
8. Gogos CA, Fouka KP, Nikigoridis G, et al. Prevalence of hepatitis B and C virus infection in the general population and selected groups in South- Eastern Greece. Eur J Epidemiol 2003;18: 551-557.
9. Goritsas C, Plerou I, Agaliotis R, et al. HCVinfection in the general population of a Greek island: prevalence and risk factors. Hepatogastroenterology 2000;44: 782-785.
10. Hagan H, Latka MH, Campell JV, et al. Eligibility for treatment of hepatitis C virus infection among injection drug users in 3 US cities. Clin Infect Dis 2006;42: 669-672.
11. Hagan H, Pouget ER, Des Jarlais DC, Lelutiu-Weinberger C. Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. Am J Epidemiol 2008;168: 1099-1109.
12. Hatzakis A, Wait S, Bruix J, et al. The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference. J Viral Hepat 2011;18(suppl 1): 1-16.
13. Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis 2009;49: 561-573.
14. Kimber J, Copeland L, Hickman M, et al. Survival and cessation in injecting drug users: prospective observational study of outcomes and effect of opiate substitution treatment. BMJ 2010;341:c3172.
15. Kwon JA, Iversen J, Maher L, Law MG, Wilson DP. The impact of needle and syringe programs on HIV and HCV transmissions in injecting drug users in Australia: a model based analysis. J Acquir Immun Defic Syndr 2009;51: 462-469.
16. Lavanchy D. The global burden of chronic hepatitis C. Liver Int 2009;29(suppl 1): 74-81.
17. Mehta S, Genberg B, Astemborski J, et al. Limited uptake of hepatitis C treatment among injection drug users. J Community Health 2008;33: 126-133.
18. Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. The Lancet 2011;378: 571-583.
19. Savvas SP, Koskinas J, Sinani C, Hadziyannis A, Spanou F, Hadziyannis SJ. Changes in epidemiological patterns of HCV infection and their impact on liver disease over the last 20 years in Greece. J Viral Hepat 2005;12: 551-557.
20. Schaefer M, Schmid F, Folwancy C, et al. Adherence and mental side effects during hepatitis C treatment with interferon alpha and ribavirin in psychiatric risk groups. Hepatology 2003;37: 443-451.
21. World Health Organization. Resolution A63/15: viral hepatitis, 63rd World Health Assembly. http://apps. who. iny/gb/ebwha/pdffiles/WHA63/A63. Accessed May 24, 2011.
22. Zacharakis G, Kotsiou S, Papoutselis M, et al. Changes in the epidemiology of hepatitis B virus infection following the implementation of immunization programmes in Northeastern Greece. Eurosurveillance 2009;14: 1-6.